Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia.
The authors studied the effects of rasagiline on cognition in a sample of 50 nondemented patients with mild to moderate Parkinson's disease (PD) using a double-blind, placebo controlled design. Cognition and motor symptoms were assessed at baseline and after 6 months of receiving either rasagiline or placebo. Participants receiving rasagiline showed improvement in their motor symptoms of PD compared to participants receiving placebo. No significant changes in performance on neuropsychological measures of cognition were observed between the groups. Rasagiline is an effective treatment for the motor symptoms of PD. Rasagiline did not appear to affect cognition during this 6-month study.
From the Memorial Hospital of Rhode Island-Medical Rehabilitation, Pawtucket, R.I. (LLF); and the Alpert Medical School of Brown University, Providence, R.I. (JHF).
Laura L
LL
Frakey
From the Memorial Hospital of Rhode Island-Medical Rehabilitation, Pawtucket, R.I. (LLF); and the Alpert Medical School of Brown University, Providence, R.I. (JHF).
Joseph H
JH
Friedman
D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018697:Nootropic Agents; C031967:rasagiline
Neuropsychology; Parkinson’s Disease